CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
复制标题
DOI：
10.1182/blood-2004-08-3175
复制
发表时间：
2005-02-15
期刊：
影响因子：
20.3
通讯作者：
Smith, P
中科院分区：
文献类型：
--
作者：
Marcus, R;Imrie, K;Smith, P
环磷酰胺、长春新碱和强的松（CVP）联合治疗是晚期滤泡性淋巴瘤的几种标准治疗方案之一。与类似的化疗方案一样，该方案的缓解率为60%至80%，中位缓解持续时间不到2年。利妥昔单抗（Rituximab）是一种抗CD20的嵌合单克隆抗体，在滤泡性淋巴瘤中具有活性，无论是单独治疗还是联合化疗。先前未接受治疗的III至IV期滤泡性淋巴瘤患者被随机分配接受8个周期的CVP加美罗华（R-CVP, n = 162）或CVP （n = 159）。R-CVP组的总缓解率和完全缓解率分别为81%和41%，而CVP组分别为57%和10% （P < 0.0001）。在中位随访30个月时，接受R-CVP治疗的患者进展时间明显延长（中位32个月vs中位CVP 15个月；P < 0.0001）。R-CVP组患者治疗失败的中位时间为27个月，CVP组为7个月（P < 0.0001）。利妥昔单抗未显著增加CVP的毒性。在CVP方案中加入利妥昔单抗可显著改善先前未经治疗的晚期滤泡性淋巴瘤患者的临床结果，且没有增加毒性。(C) 2005年由美国血液病学会出版。
The combination of cyclophosphamide, vincristine, and prednisone (CVP) is one of several standard treatment options for advanced follicular lymphoma. This, like similar chemotherapeutic regimens, induces response rates of 60% to 80%, with a median response duration of under 2 years. Rituximab, a chimeric monoclonal antibody against CD20, is active in follicular lymphoma, both as monotherapy and in combination with chemotherapy. Previously untreated patients with stages III to IV follicular lymphoma were randomly assigned to receive either 8 cycles of CVP plus rituximab (R-CVP; n = 162) or CVP (n = 159). Overall and complete response rates were 81% and 41% in the R-CVP arm versus 57% and 10% in the CVP arm, respectively (P < .0001). At a median follow-up of 30 months, patients treated with R-CVP had a very significantly prolonged time to progression (median 32 months versus 15 months for CVP; P < .0001). Median time to treatment fail-ure was 27 months in patients receiving R-CVP and 7 months in the CVP arm (P < .0001). Rituximab did not add significantly to the toxicity of CVP. The addition of rituximab to the CVP regimen significantly improves the clinical outcome in patients with previously untreated advanced follicular lymphoma, without increased toxicity. (C) 2005 by The American Society of Hematology.